摘要
目的:探讨复方丹参滴丸对冠心病阿司匹林抵抗患者二磷酸腺苷(ADP)、花生四烯酸(AA)诱导的血小板聚集率的影响。方法:根据AA和ADP作为诱导剂测定的血小板聚集功能,将39例阿司匹林抵抗患者随机分为2组。A组为常规阿司匹林治疗组(n=19),B组为阿司匹林联合复方丹参滴丸治疗组(n=20)。分别在治疗前以及治疗1个月后测定由ADP、AA诱导的血小板聚集率,比较2组治疗前后及治疗后不同组别上述指标的差异。结果:阿司匹林联合复方丹参滴丸治疗1个月后,可使冠心病阿司匹林抵抗患者血小板聚集率下降,与治疗前比较有显著性差异[(49.46%±5.18%)比(73.81%±2.86%),P=0.048 9];可使冠心病患者血尿酸水平下降,B组治疗后血尿酸水平为(421.69±34.01)μmol/L,较治疗前[(444.69±50.88)μmol/L]明显下降(P=0.038 9),与A组治疗后[(444.88±21.32)μmol/L]相比明显下降(P=0.042 2)。2组患者在治疗中未出现不良临床事件。结论:复方丹参滴丸对冠心病阿司匹林抵抗患者有抗血小板聚集作用,并且治疗后可降低血尿酸水平。
Objective To investigate the effect of compound Danshen dripping pill on aspirin resistance （AR） tested by arachidonic acid （AA） and adenosine diphosphate （ADP） induced platelet aggregation in patients with coronary artery disease. Methods A total of 39 coronary artery disease patients with AR were randomly assigned into group A （n=19） treated with aspirin alone and group B （n=20） treated with a combination of aspirin and compound Danshen dripping pill. AA and ADP induced platelet aggregation rates were measured before and one month after treatment, and the results were compared. Results In group B, AA and ADP induced platelet aggregation rate was significantly lower after one month treatment than that before treatment （69.46%±5.18% vs. 73.81%±2.86%, P=0.048 9）; blood uric acid level was significantly lower after one month treatment than that before treatment[（421.69±34.01） μmol/L vs. （444.69±50.88） μmol/L, P=0.038 9], which was also lower than that in group A [（444.88±21.32） μmol/L , P=0.042 2]. No adverse event was observed in both groups. Conclusions Compound Danshen dripping pill has antiplatelet effect in coronary artery disease patient with AR, and can reduce uric acid level.
出处
《内科理论与实践》
2013年第3期200-203,共4页
Journal of Internal Medicine Concepts & Practice
关键词
阿司匹林抵抗
复方丹参滴丸
血小板聚集率
尿酸
Aspirin resistance
Compound Danshen dripping pill
Platelet aggregation
Blood uric acid
